scholarly journals Comparative study on Pharmacokinetic Profiles of Chicken IgY to Horse IgG in Rabbits

2018 ◽  
Vol 68 (3) ◽  
pp. 405
Author(s):  
ZHAOXIANG ZHOU ◽  
JIAN WANG ◽  
SONG GAO ◽  
HAO REN ◽  
WENYAN XIE ◽  
...  
Keyword(s):  
Tetanus Toxoid ◽  
Indirect Elisa ◽  
Compartmental Analysis ◽  
The Body ◽  
Rabbit Serum ◽  
Pharmacokinetic Parameters ◽  
White Leghorn ◽  
White Leghorn Chicken ◽  
Pharmacokinetic Profiles ◽  
Egg Yolks

Chicken IgY antibody has been extensively reported for various applications as an alternative to mammalian IgG. To evaluated the pharmacokinetics profile of chicken IgY in comparison with horse IgG. Chicken IgY antibody was prepared by immunizing the white leghorn chicken with tetanus toxoid (TT) and then extracted anti-TT-IgY from immune egg yolks by PEG-6000 extraction. The titer of anti-TT-IgY was determined by ELISA in order to select the hyper immune eggs for further extraction. Rabbits were injected with 300 μg/kg of Chicken IgY and horse IgG by intravenous (i.v.) and intramuscular (i.m.) administrations. Then, the concentrations of IgY and IgG in rabbit serum were determined using indirect ELISA. Pharmacokinetic parameters were estimated using non-compartmental analysis. IgY can reach higher concentration (Cmax= 4.54 mg/L after i.m. injection) within shorter time (Tmax= 0.12 h after i.m. injection) than IgG (Cmax= 3.99 ng/mL after i.m. injection; Tmax=0.11 h after i.m. injection), while the IgY lifespan (T1/2=26.98 h and 31.98 h after i.v. and i.m. administration, respectively) in the body was comparable with IgG (T1/2=27.94 h and 29.58 h after i.v. and i.m. administration, respectively). IgY might be a promising choice as an alternative to mammalian sourced antibodies.

scholarly journals  Comparative single intraperitoneal dose pharmacokinetics of aspirin and acetaminophen in chicks

2012 ◽  
Vol 57 (No. 3) ◽  
pp. 121-124 ◽  
Author(s):  
FK Mohammad ◽  
AS Mansoor ◽  
MHI Al-Zubaidy
Keyword(s):  
Intraperitoneal Administration ◽  
Compartmental Analysis ◽  
The Body ◽  
Pharmacokinetic Parameters ◽  
Limited Information ◽  
Spectrophotometric Methods ◽  
Elimination Half ◽  
Toxicological Studies ◽  
Intraperitoneal Dose ◽  
Total Body

Limited information is available on the pharmacokinetics and bioavailability of aspirin and acetaminophen in young chicks. The purpose of the present study was to examine the pharmacokinetics of acetyl salicylic acid (aspirin) and acetaminophen in 12-day old chicks after a single intraperitoneal administration of each drug alone at the dose of 100 mg/kg body weight. Blood samples were collected from chicks (six/each time period) at 10, 20, 30, 60 and 120 min after each drug administration. The concentrations of aspirin and acetaminophen in the plasma were determined by spectrophotometric methods. The pharmacokinetic parameters of the drugs were calculated by a non-compartmental analysis. The elimination half-lives of aspirin and acetaminophen were 1.68 and 1.36 h with steady state volume of distributions 0.079 and 1.11 l/kg and total body clearances of 0.029 and 0.53 l/h/kg, respectively. The mean residence times of the drugs were 2.74 and 2.09 h and their area under the plasma concentration-time curves (0–∞) were 3486 and 188 μg/h/ml, respectively. In conclusion, the data show the pharmacokinetic profiles of single intraperitoneal doses of aspirin and acetaminophen in chicks and suggest that acetaminophen is well distributed in the body of the chicks and eliminated faster from the body compared to aspirin. These parameters should be taken into consideration in further therapeutic and toxicological studies of drugs in chickens.  

scholarly journals Quantitative and Qualitative Protein Changes in the Developing Single Comb White Leghorn Chicken Embryo

1972 ◽  
Vol 51 (1) ◽  
pp. 313-320 ◽  
Author(s):  
J.A. Asmar ◽  
P.L. Pellett ◽  
Nur Hariri ◽  
M.D. Hariri
Keyword(s):  
Chicken Embryo ◽  
White Leghorn ◽  
White Leghorn Chicken ◽  
Single Comb

Ketamine kinetics: decerebrate vs. intact cats

1979 ◽  
Vol 57 (8) ◽  
pp. 878-881 ◽  
Author(s):  
James E. Heavner ◽  
Duane C. Bloedow
Keyword(s):  
Apparent Volume ◽  
Volume Of Distribution ◽  
Drug Dose ◽  
The Body ◽  
Pharmacokinetic Parameters ◽  
Peripheral Compartment ◽  
Blood Concentrations ◽  
Open Model ◽  
Apparent Volume Of Distribution ◽  
Compartment Open Model

Pharmacokinetic parameters of a ketamine (10 mg/kg, iv) bolus in decerebrate and intact cats were compared. A two-compartment open model best described the data in both groups. The apparent volume of distribution of the peripheral compartment, the apparent volume of distribution of the drug in the body, and the half-life of the postdistributive phase were significantly less (p < 0.05) in the decerebrate animals. These results emphasize the importance of correlating behavior and neuronal activity with plasma or blood concentrations of drug in animals rather than assuming that, for a given drug dose, blood (and thus tissue) levels of the agent will be similar regardless of how the animal is prepared for study.

scholarly journals Herb-Drug Interaction betweenEchinacea purpureaand Darunavir-Ritonavir in HIV-Infected Patients

2010 ◽  
Vol 55 (1) ◽  
pp. 326-330 ◽  
Author(s):  
José Moltó ◽  
Marta Valle ◽  
Cristina Miranda ◽  
Samandhy Cedeño ◽  
Eugenia Negredo ◽  
...  
Keyword(s):  
High Performance ◽  
Geometric Mean ◽  
Echinacea Purpurea ◽  
The Body ◽  
Pharmacokinetic Parameters ◽  
Root Extract ◽  
Open Label ◽  
Fixed Sequence ◽  
Time Curve ◽  
Sequence Study

ABSTRACTThe aim of this open-label, fixed-sequence study was to investigate the potential ofEchinacea purpurea, a commonly used botanical supplement, to interact with the boosted protease inhibitor darunavir-ritonavir. Fifteen HIV-infected patients receiving antiretroviral therapy including darunavir-ritonavir (600/100 mg twice daily) for at least 4 weeks were included.E. purpurearoot extract capsules were added to the antiretroviral treatment (500 mg every 6 h) from days 1 to 14. Darunavir concentrations in plasma were determined by high-performance liquid chromatography immediately before and 1, 2, 4, 6, 8, 10, and 12 h after a morning dose of darunavir-ritonavir on days 0 (darunavir-ritonavir) and 14 (darunavir-ritonavir plus echinacea). Individual darunavir pharmacokinetic parameters were calculated by noncompartmental analysis and compared between days 0 and 14 with the geometric mean ratio (GMR) and its 90% confidence interval (CI). The median age was 49 (range, 43 to 67) years, and the body mass index was 24.2 (range, 18.7 to 27.5) kg/m2. Echinacea was well tolerated, and all participants completed the study. The GMR for darunavir coadministered with echinacea relative to that for darunavir alone was 0.84 (90% CI, 0.63-1.12) for the concentration at the end of the dosing interval, 0.90 (90% CI, 0.74-1.10) for the area under the concentration-time curve from 0 to 12 h, and 0.98 (90% CI, 0.82-1.16) for the maximum concentration. In summary, coadministration ofE. purpureawith darunavir-ritonavir was safe and well tolerated. Individual patients did show a decrease in darunavir concentrations, although this did not affect the overall darunavir or ritonavir pharmacokinetics. Although no dose adjustment is required, monitoring darunavir concentrations on an individual basis may give reassurance in this setting.

Removal of Vancomycin during Plasmapheresis

1997 ◽  
Vol 31 (10) ◽  
pp. 1132-1136 ◽  
Author(s):  
Syble D McClellan ◽  
Charles H Whitaker ◽  
Richard C Friedberg
Keyword(s):  
Tertiary Care ◽  
Compartment Model ◽  
The Body ◽  
Patient Specific ◽  
Pharmacokinetic Parameters ◽  
Serum Concentrations ◽  
Total Clearance ◽  
Concentration Data ◽  
Vancomycin Concentration ◽  
Total Body

OBJECTIVE: To examine the removal of vancomycin during plasmapheresis, determine whether drug administration should be withheld prior to or a supplemental dose given after the procedure, and determine whether a redistribution phenomenon in vancomycin serum concentrations occurs after plasmapheresis. DESIGN: Prospective, cohort study. SETTING: An 800-bed, tertiary-care, teaching hospital. PATIENTS: Twelve patients receiving vancomycin as prescribed who were also undergoing therapeutic plasmapheresis. METHODS: Blood samples for determination of vancomycin concentrations were obtained from each patient immediately before, during, immediately after, and 2 hours after plasmapheresis. Vancomycin concentration in plasma removed by plasmapheresis and volume of plasma removed were measured. Patient-specific pharmacokinetic parameters were determined for each patient using serum concentration data and a one-compartment model. Percent of drug removed by plasmapheresis and percent increase in vancomycin total clearance secondary to plasmapheresis were calculated. RESULTS: A mean of 6.3% of the total body store of vancomycin was removed by plasmapheresis. Vancomycin clearance during plasmapheresis averaged 1.6 L/h, which was an average increase of 285% in the total clearance of vancomycin from the body. Nine of 10 patients had a higher observed vancomycin concentration 2 hours after plasmapheresis than that predicted by degrading the concentration observed immediately after the procedure, suggesting that redistribution in serum concentrations occurs after the procedure. CONCLUSIONS: A single one-volume plasmapheresis does not remove a clinically important amount of vancomycin; therefore, supplemental dosing after the procedure is not necessary. A redistribution phenomenon in vancomycin concentrations appears to exist after plasmapheresis. Further study is needed to determine how long the redistribution phase lasts and when vancomycin concentrations should be measured after plasmapheresis.

The sclerotic plates of the White Leghorn chicken

1942 ◽  
Vol 84 (3) ◽  
pp. 295-306 ◽  
Author(s):  
Norman M. Nelson
Keyword(s):  
White Leghorn ◽  
White Leghorn Chicken

Pharmacokinetics and bioequivalence of generic etoricoxib in healthy volunteers

2021 ◽  
Vol 10 (3) ◽  
pp. 113-118
Author(s):  
Nishalini Harikrishnan ◽  
Ka-Liong Tan ◽  
Kar Ming Yee ◽  
Alia Shaari Ahmad Shukri ◽  
Nalla Ramana Reddy ◽  
...  
Keyword(s):  
Compartmental Analysis ◽  
Bioequivalence Study ◽  
Active Pharmaceutical Ingredient ◽  
Pharmacokinetic Profile ◽  
Time Profile ◽  
Pharmacokinetic Parameters ◽  
Open Label ◽  
Reference Drug ◽  
Test Formulation ◽  
R Ratio

Introduction/Study Objectives: A bioequivalence study was performed to compare the pharmacological profile of innovator etoricoxib (ETO) with a newly developed generic ETO, both in a 120 mg tablet formulation. A dissolution study was conducted to optimize the formulation process before evaluating physical changes in the active pharmaceutical ingredient and the formulated product. Methods: This was a randomized, open-label, balanced, two-treatment, two-period, two-sequence, single-dose, two-way crossover, truncated bioequivalence study involving a washout period of ten days. A total of 26 healthy male volunteers were recruited. The pharmacokinetic profile of the test formulation was compared with the reference formulation. Results/Discussion: The pharmacokinetic parameters of ETO were calculated based on the plasma drug concentration-time profile using non-compartmental analysis to determine its safety profile and tolerability. The Test/Reference (T/R) ratio of ETO was 104.36% (90% confidence interval (CI): 98.30%–110.80%) for area under curve (AUC)0-72 while the T/R ratio of maximum concentration (Cmax) was 101.39% (92.15%–111.56%). The 90% CI of the Cmax and AUC0-72 of ETO were within acceptable bioequivalence limits of 80%–125%. All values were within the predetermined limits of the Association of Southeast Asian Nation (ASEAN) bioequivalence guidelines. Conclusion: The test formulation was found to be bioequivalent with respect to the reference drug, according to ASEAN bioequivalence guidelines.

scholarly journals Pharmacokinetic Profile of μSMIN Plus™, a new Micronized Diosmin Formulation, after Oral Administration in Rats

2015 ◽  
Vol 10 (9) ◽  
pp. 1934578X1501000 ◽  
Author(s):  
Rosario Russo ◽  
Angelo Mancinelli ◽  
Michele Ciccone ◽  
Fabio Terruzzi ◽  
Claudio Pisano ◽  
...  
Keyword(s):  
Oral Administration ◽  
Plasma Concentrations ◽  
Compartmental Analysis ◽  
Pharmacokinetic Profile ◽  
Pharmacokinetic Parameters ◽  
Maximum Plasma ◽  
Sprague Dawley ◽  
Time Curve ◽  
Maximum Plasma Drug Concentration

Diosmin is a naturally occurring flavonoid present in citrus fruits and other plants belonging to the Rutaceae family. It is used for the treatment of chronic venous insufficiency (CVI) for its pheblotonic and vaso-active properties, safety and tolerability as well. The aim of the current in vivo study was to investigate the pharmacokinetic profile of a branded micronized diosmin (μSMIN Plus™) compared with plain micronized diosmin in male Sprague-Dawley rats. After oral administration by gastric gavage, blood samples were collected via jugular vein catheters at regular time intervals from baseline up to 24 hours. Plasma concentrations were assessed by LC/MS. For each animal, the following pharmacokinetic parameters were calculated using a non-compartmental analysis: maximum plasma drug concentration (Cmax), time to reach Cmax (Tmax), area under the plasma concentration-time curve (AUC0-last), elimination half-life (t1/2), and relative oral bioavailability (%F). The results of the current study clearly showed an improvement in the pharmacokinetic parameters in animals treated with μSMIN Plus™ compared with animals treated with micronized diosmin. In particular, μSMIN Plus™ showed a 4-fold increased bioavailability compared with micronized diosmin. In conclusion, the results from the current study provided a preliminary pharmacokinetic profile for μSMIN Plus™, which may represent a new tool for CVI management.

scholarly journals Pharmacokinetics of thiamphenicol in normal and pasteurella multocida infected lactating goats

2017 ◽  
Vol 5 (2) ◽  
pp. 61
Author(s):  
Mossad Elsayed ◽  
Ashraf Elkomy ◽  
Faten Ibrahim
Keyword(s):  
Intravenous Injection ◽  
Pasteurella Multocida ◽  
The Body ◽  
Pharmacokinetic Parameters ◽  
Time Curve ◽  
Once Daily ◽  
Intramuscular Dose ◽  
Lactating Goats ◽  
Urine Concentrations ◽  
Repeated Administrations

The pharmacokinetic parameters of thiamphenicol following intravenous and intramuscular (single & repeated) administrations were estimated in normal and experimentally pasteurella multocida infected goats. Following a single intravenous injection of 30 mg thiamphenicol /kg b.wt. in normal goats, thiamphenicol could be detected therapeutically for 24 hours post intravenous injection. The serum concentration – time curve of thiamphenicol following intravenous injection showed that the drug obeyed a two compartments open model. The intramuscular bioavailability of thiamphenicol in normal goats was 66.63 %. Intramuscular injection of 30 mg thiamphenicol per kilogram body weight once daily for five consecutive days in normal and pastreulla multocida infected goats revealed a lower significant serum thiamphenicol concentration in pastreulla multocida infected goats compared with normal goats, also it’s found that: marked significant decrease in ( k1, K12, K21, T0.5(α) , T0.5(β), Tmax and CLtot in normal compared with infected goats, on the other hand a significant increase in Cmax,AUC, C0,B and β in normal compared with infected goats. Thiamphenicol was cleared by all clearance processes (Cltot) in the body at significant faster rates in Pasteurella multocida infected goats than in normal goats. The concentrations of thiamphenicol in milk were significantly lower in Pasteurella multocida infected goats than in normal goats. The mean peak urine concentrations of thiamphenicol were reached 4 hours after each intramuscular dose with a lower significant concentration in Pasteurella multocida infected goats than in normal goats.

Sign in / Sign up

Export Citation Format

Share Document